TABLE 2.

Treatment of HSV isolates with zinc gluconate or zinc lactate^a

Treatment and HSV type isolate no.b	Mean ± SD PFU		% Inactivation
	Mock-treated HSV	Zn-treated HSV
Zn gluconate + glycine
HSV-1, 2	222 ± 28	0	100
HSV-1, 3	150 ± 1	1.7 ± 2.8	98.9
HSV-1, 4	274 ± 19	0	100
HSV-1, 14	220 ± 8	0	100
HSV-1, 18	342 ± 57	0	100
HSV-2, 1	98 ± 17	0.3	99.7
HSV-2, 8	42 ± 8	0.3	99.3
HSV-2, 16	219 ± 23	163 ± 24	25.5
HSV-2, 19	239 ± 43	133 ± 23	44.4
HSV-2, 20	84 ± 9	60 ± 2	28.6
Zn lactate
HSV-1, 2	263 ± 23	0.7	99.8
HSV-1, 3	173 ± 3	4.3 ± 1	97.5
HSV-1, 4	321 ± 23	0	100
HSV-1, 14	252 ± 47	0	100
HSV-1, 18	388 ± 61	0.3	99.9
HSV-2, 1	112 ± 10	0	100
HSV-2, 8	37 ± 7	6 ± 3	83.7
HSV-2, 16	322 ± 48	6 ± 1	98
HSV-2, 19	405 ± 26	4.3 ± 1	98.9
HSV-2, 20	91 ± 19	0.7	99.2

^aTreatment was with 50 mM zinc for 120 min at 37°C. All plaque counts are the averages for three wells. 

^bBy the Wilcoxon rank sum test for HSV-1 inactivation by the zinc salt versus HSV-2 inactivation by the same salt, P was 0.028 for zinc gluconate plus glycine, and P was 0.25 for zinc lactate.